Palvella Therapeutics Inc.
Organization details
- Legal name
- Palvella Therapeutics Inc.
- Former names
- Pieris Pharmaceuticals, INC. Marika Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Wayne
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PVLA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001583648
- EIN
- 30-0784346
Board of directors
-
Ann Barbier · DirectorSince 2023
-
Christopher P. Kiritsy · DirectorSince 2023
-
Elaine J. Heron · DirectorSince 2024
-
George M. Jenkins · DirectorSince 2024
-
James A. Geraghty · DirectorSince 2023
-
John Doux · DirectorSince 2026
-
Matthew L. Sherman · DirectorSince 2023
-
Matthew Pauls · DirectorSince 2026
-
Maya R. Said · DirectorSince 2023
-
Michael Richman · DirectorSince 2023
-
Peter A. Kiener · DirectorSince 2023
-
Stephen S. Yoder · Director · Chief Executive OfficerSince 2023
-
Tadd S. Wessel · DirectorSince 2024
-
Todd C. Davis · DirectorSince 2024
-
Wes Kaupinen · Director · President and CEOSince 2024
Chief executives
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.8%
-
97.4%
-
97.9%
Board connections
6 of this board's directors also sit on 8 other boards. 8 are in the same sector.
-
Pelthos Therapeutics Inc. Same sectorvia Matthew Pauls and Todd C. Davis
-
BioMarin Pharmaceutical Inc. Same sectorvia Elaine J. Heron
-
Cue Biopharma Inc. Same sectorvia Peter A. Kiener
-
Fulcrum Therapeutics Inc. Same sectorvia James A. Geraghty
-
Ligand Pharmaceuticals Incorporated Same sectorvia Todd C. Davis
-
NextCure Inc. Same sectorvia Michael Richman
-
Savara Inc. Same sectorvia Matthew Pauls
-
Voyager Therapeutics Inc. Same sectorvia James A. Geraghty
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $849,974
- 3 purchases by 2 insiders
- Sold, last 12 months
- $12,343,194
- 59 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 11, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Option exercise | +6,250 | $9.79 | $61,188 |
| Nov 11, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −1,650 | $164.14 | $270,835 |
| Nov 11, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −1,467 | $165.78 | $243,196 |
| Nov 11, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −1,133 | $166.76 | $188,942 |
| Nov 11, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −1,200 | $167.75 | $201,299 |
| Nov 11, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −600 | $168.73 | $101,240 |
| Nov 11, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −200 | $169.78 | $33,956 |
| Nov 10, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Option exercise | +4,266 | $7.53 | $32,123 |
| Nov 10, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Option exercise | +1,984 | $9.79 | $19,423 |
| Nov 10, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −100 | $163.34 | $16,334 |
| Nov 10, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −1,449 | $164.85 | $238,871 |
| Nov 10, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −1,651 | $165.85 | $273,814 |
| Nov 10, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −1,500 | $166.91 | $250,369 |
| Nov 10, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −200 | $167.81 | $33,562 |
| Nov 10, 2026 | Martini Jeffrey S Officer (Chief Scientific Officer) | Open-market sale | −550 | $169.03 | $92,965 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Palvella Therapeutics Inc.
Who is the CEO of Palvella Therapeutics Inc.?
Wes Kaupinen has been Palvella Therapeutics Inc.'s President and CEO since December 2024.
How many directors are on Palvella Therapeutics Inc.'s board?
Palvella Therapeutics Inc.'s board has 15 directors: Ann Barbier, Christopher P. Kiritsy, Elaine J. Heron, George M. Jenkins, James A. Geraghty, John Doux, Matthew L. Sherman, Matthew Pauls, Maya R. Said, Michael Richman and 5 others.
Are Palvella Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Palvella Therapeutics Inc. insiders bought $849,974 of shares in 3 purchases and sold $12.3 million of shares in 59 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="palvella-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.